Business
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in
About this update from Summit Therapeutics Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nSummit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 09, 2023, at 3:45 PM PST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Co-Chief Executive Officer and President, will provide details regarding our Company following the announcement of our agreement to in-license the breakthrough innovative bispecific antibody, ivonescimab (SMT112).\n\nIn addition to live attendance at the conference, the audio presentation will be available live from our website: www.summittxinc.com.\n\nAs a reminder, we will also be hosting a Special Meeting of Stockholders on Friday, January 06, 2023, at 10:00 AM PST.\n\nSummit Therapeutics’ Mission Statement\n\nTo build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, and successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.\n\nWe accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.\n\nAbout Summit Therapeutics\n\nSummit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK and Cambridge, UK.\n\nFor more information, please visit https://w...